InvisiDerm Healthcare Launches Revolutionary Noninvasive Oxygen Therapy Device into Spa, Health, and Beauty Market

Share Article

InvisiDerm Healthcare has announced that it is launching the initial application of its groundbreaking transdermal delivery device for oxygen therapy, D’Oxyva™, into the spa, health-and-beauty, and anti-aging markets.

InvisiDerm Healthcare's D’Oxyva™ for transdermal oxygen therapy

InvisiDerm Healthcare's D’Oxyva™ for transdermal oxygen therapy

InvisiDerm's D’Oxyva™ oxygen therapy delivers lasting health and beauty benefits from the inside out.

InvisiDerm Healthcare (“InvisiDerm” or “the Company”), an emerging developer and manufacturer of novel transdermal drug delivery (TDD) methods, has announced that it is launching the initial application of its groundbreaking oxygen therapy delivery device, D’Oxyva™, into the spa, health-and-beauty, and anti-aging markets.

Oxygen therapy treatment with InvisiDerm technology generates a number of beneficial health and anti-aging effects, including detoxification of the body, stress relief, fat reduction, decreased severity of wrinkles and scars, and more balanced blood pH. In addition, the therapy also increases the effectiveness of additional skin applications including creams, mud-wraps, and wound dressings.

The patent-pending D’Oxyva™ functions by delivering carbon dioxide (CO2) as part of a super saturated CO2 + H2O Vapor™ to the skin’s sweat pores and glands, free of needles, pressure, pain, and side effects. The CO2 signals the blood cells to deliver additional oxygen where it is most needed, providing higher oxygen levels that boost the health and beauty of the skin and other bodily processes.

As the body’s first line of defense, healthier skin produced by D’Oxyva™ oxygen therapy plays a critical role in boosting immunity to environmental agents such as cancer-causing chemicals and sunlight. The increased levels of blood flow with oxygen-rich blood cells also act as a calming and relaxing effect on the mind and the nervous system. InvisiDerm has demonstrated proof of concept via preclinical pilot tests.

Many competing transdermal methods such as carboxytherapy attempt to produce results by invasively forcing change agents into the body. Other beauty and skin health products have long been an assortment of topical lotions and creams that fail to address the bodily functions that actually control skin health. InvisiDerm’s breakthrough therapy instead naturally improves overall health and beauty “from the inside out” in a single 5 minute treatment.

Noting that D’Oxyva™ has a much more gentle – and effective – method of transdermally delivering its active substance, CO2, InvisiDerm CEO Norbert Kiss stated, “Because we deliver CO2, the precursor to natural oxygen therapy, in unison with the body’s natural processes, it is not surprising that InvisiDerm is able to create systemic change for the longer term. Our method produces superior results for health and beauty – from the inside out.”

D’Oxyva™ therapy has its roots in the age-old method of “taking a cure” using balneotherapy – a CO2 bath, usually at a spa. This therapy has been prescribed for centuries in Europe, Japan and elsewhere to treat a variety of physical conditions. InvisiDerm’s technology makes it possible for clients to receive a much more concentrated version of the treatment without having to spend weeks at a spa.

Initial sales to the spa, health-and–beauty, and anti-aging markets will be taking place through a network of distributors that specialize in the field. InvisiDerm’s flagship distributor is Dr. Reinhard Bergel, founder and head of H-E-A-T Spa Kur Therapy Development Inc., and one of the most influential thought-leaders in the industry.

Commenting on the launch of InvisiDerm’s new product, Dr. Bergel stated, “I have followed the cutting edge technology development of InvisiDerm’s D’Oxyva™ device, and I am extremely optimistic about its potential to transform the health of spa-treatment clients throughout the world. I am excited to have the opportunity to play a significant role in launching the InvisiDerm product. It could not be simpler and more efficient.”

About InvisiDerm Healthcare (http://www.MyInvisiDerm.info)
InvisiDerm, LLC, d/b/a/ InvisiDerm Healthcare, is an early stage medical device company in the United States that designs, develops, manufactures and markets groundbreaking, proprietary, truly noninvasive, and highly portable medical gas-powered transdermal delivery devices and accessories made in the USA. The Company has started manufacturing and marketing its initial product line in 2011, using its D’Oxyva™ oxygen therapy platform to target the spa, health-and–beauty, and anti-aging markets. More broadly, InvisiDerm is aiming to make hypodermic needle drug delivery obsolete and rapidly revolutionize the double-digit growth, multi-billion dollar transdermal drug delivery (TDD) industry with its next-generation products. The Company is a spin-out of The NKGroup and is headquartered in Pasadena, California.

Forward-Looking Information
This press release may contain “forward-looking information”. This forward-looking information includes, or may be based upon, estimates, forecasts, and statements as to management’s expectations with respect to, among other things, the quality of the products of InvisiDerm Healthcare, its resources, progress in development, and demand and market outlook for noninvasive transdermal delivery medical devices in general. Forward-looking information is based on the opinions and estimates of management at the date the information is given, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. These factors include the inherent risks involved in the launch of a new medical device, the uncertainties involved in innovation and market acceptance, fluctuating component and other raw and advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and InvisiDerm Healthcare assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. InvisiDerm Healthcare makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

For More Information
Please visit http://www.MyInvisiDerm.info and send your general inquiries via the Contact Us page, or for specific inquiries contact InvisiDerm Public Relations at pr(at)myinvisiderm(dot)info or by phone at +1 (626) 240-0956.

Copyright © 2011 InvisiDerm Healthcare. All rights reserved. The InvisiDerm star logo, InvisiDerm, and D’Oxyva are either registered trademarks or trademarks of InvisiDerm Healthcare in the United States and other countries.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Norbert Kiss, CEO
Visit website